Skip to main content

Table 2 Quality assessment of the included studies according to Cochrane collaboration’s tool for assessing risk of bias

From: Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Included studies Randomized
methods
Blind methods Allocation concealment Incomplete outcome data Selective
reporting
Other
biases
POLLUX Low risk Unclear Unclear Low risk Unclear Unclear
CASTOR Low risk Unclear Unclear Low risk Unclear Unclear
NCT02252172 Low risk Unclear Unclear Low risk Unclear Unclear
ALCYONE Low risk High risk Unclear Low risk Unclear Unclear
ICARIA - MM Low risk High risk Unclear Low risk Unclear Unclear
CASSIOPEIA Low risk High risk Unclear Low risk Unclear Unclear
KEYNOTE-183 Low risk High risk Unclear High risk Unclear Unclear
KEYNOTE-185 Low risk High risk Unclear High risk Unclear Unclear
NCT01478048 Low risk High risk Unclear Low risk Unclear Unclear
ELOQUENT-3 Low risk Unclear Unclear Low risk Unclear Unclear
ELOQUENT-2 Low risk Unclear Unclear Low risk Unclear Unclear